# A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo

> **NCT06905873** · PHASE1 · RECRUITING · sponsor: **Forte Biosciences, Inc.** · enrollment: 64 (estimated)

## Conditions studied

- Vitiligo

## Interventions

- **DRUG:** FB102
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06905873
- **Lead sponsor:** Forte Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-25
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06905873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06905873, "A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT06905873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*